Your Health. Your Family. Your Choice.
|History of Changes from the VAERS Wayback Machine|
|Vaccination / Manufacturer||Lot / Dose||Site / Route|
|COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH||ET1831 / 1||- / OT|
Administered by: Other Purchased by: ??
Symptoms: Chills, Drug ineffective, Urosepsis, Acute kidney injury, Clostridium test, COVID-19, SARS-CoV-2 test
Life Threatening? No
Birth Defect? No
Permanent Disability? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Other Medications: EUCREAS; APO-FAMOTIDIN; ASA PROTECT PHARMAVIT; BISOBLOCK; COVERCARD PLUS; MILURIT; SPIRIVA; VALONGIX
Preexisting Conditions: Medical History/Concurrent Conditions: Anal fistula; Appendectomy; Atherosclerosis generalised; Diabetes mellitus; Hypertension; Hyperuricaemia; Obesity; Pneumonia; Polyarthritis; Renal insufficiency; Spondylosis; Vertebrobasilar insufficiency
Diagnostic Lab Data: Test Name: Clostridium test positive; Test Result: Positive ; Test Date: 20210319; Test Name: COVID-19 antigen test negative; Test Result: Negative ; Test Date: 20210320; Test Name: COVID-19 PCR test positive; Test Result: Positive
CDC 'Split Type': HUPFIZER INC2021559798
Write-up: COVID-19 infection; drug ineffective/COVID-19; Acute renal insufficiency; Urosepsis; chills without fever; This is a spontaneous report from a contactable physician downloaded from the Regulatory Authority-WEB HU-OGYI-288921. A 77-year-old male patient received the first dose of BNT162B2 (COMIRNATY, concentrate for dispersion for injection tozinameran (COVID-19 mRNA Vaccine embedded in lipid nanoparticles), lot number: ET1831, expiry date: unknown: BioNTech Manufacturing Pfizer) intramuscularly on 05Mar2021 at 0.3 ml single dose for COVID-19 immunization. Medical history included appendectomy, anal fistula, diabetes mellitus, hypertension, hyperuricemia, obesity, pneumonia, polyarthritis, renal insufficiency, spondylosis, vertebrobasilar insufficiency and generalized atherosclerosis. Concomitant drugs were hydrochloride/vildagliptin (EUCREAS), famotidine (APO-FAMOTIDIN), acetylsalicylic acid (ASA PROTECT PHARMAVIT), bisoprolol fumarate (BISOBLOCK), amlodipine besilate, indapamide/ perindopril arginine (COVERCARD PLUS), allopurinol (MILURIT), tiotropium bromide (SPIRIVA) and amlodipine besilate/atorvastatin calcium/ perindopril arginine (VALONGIX). On 19Mar2021 the patient was admitted in the hospital because of urosepsis, acute renal insufficiency and needed mechanical ventilation. Before hospitalization, the patient was experiencing chills for 2 days without fever. A covid antigen test was done in the ambulance which came back negative on 19Mar2021, but on 20Mar2021 a PCR test confirmed the Covid-19 infection. On 03Apr2021 the patient passed away. It was unknown if autopsy was done. The direct cause of death was COVID-19. The outcome of events urosepsis, acute renal insufficiency, COVID-19 was reported as fatal ( urosepsis, acute renal insufficiency were not reported as cause of death), outcome of chills was unknown. Sender Comment: The causal relationship is unlikely between the suspected drug and the adverse events as the cause of death was determined to be Covid-19. The case is considered serious because the outcome was fatal. Further information is not expected. No follow-up attempts are needed. No further information is expected.; Reported Cause(s) of Death: COVID-19
Copyright © 2022 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166